Home > Insider Trading > Filing (0001104659-19-068984)

Filing Details

Accession Number:: 0001104659-19-068984
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-02 16:30:39
Reporting Period:: 2019-11-27

Accepted Time:: 2019-12-02 16:30:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1384859	Peter Kolchinsky	200 Berkeley Street, 18Th Floor Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-11-27	368,700	$24.04	275,176	No	4	S	Indirect	See Note
Common Stock	Disposition	2019-11-29	138,000	$24.22	137,176	No	4	S	Indirect	See Note
Common Stock	Disposition	2019-12-02	137,176	$24.98	0	No	4	S	Indirect	See Note

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Note
No	4	S	Indirect	See Note
No	4	S	Indirect	See Note

Footnotes

The securities sold include (a) 331,418 shares of Common Stock by RA Capital Healthcare Fund, L.P. (the "Fund") and (b) 37,282 shares of Common Stock by a separately managed account (the "Account").
This transaction was executed in multiple trades at prices ranging from $23.36 to $24.25; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP") of which Dr. Peter Kolchinsky is a managing member. Dr. Kolchinsky disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a)(2) under the Exchange Act except to the extent of his pecuniary interest therein.
The securities sold include (a) 124,046 shares of Common Stock by the Fund and (b) 13,954 shares of Common Stock by the Account.
This transaction was executed in multiple trades at prices ranging from $23.83 to $24.465; the price reported above reflects the weighted average sale price.
The securities sold include (a) 123,305 shares of Common Stock by the Fund and (b) 13,871 shares of Common Stock by the Account.
This transaction was executed in multiple trades at prices ranging from $24.03 to $26.23; the price reported above reflects the weighted average sale price.